Corbus Pharmaceuticals(CRBP) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CRBP Corbus Pharmaceuticals

Watchlist

6.4200
-0.4900-7.09%

Close Mar 13 16:00 ET

6.5000
+0.0800+1.25%

Post 16:55 ET

78.53MMarket Cap-1.74P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Lowers Price Target to $50
BenzingaMar 12 07:35 ET · Ratings
Corbus Pharmaceuticals (CRBP) Gets a Buy From RBC Capital
TipRanksMar 12 06:38 ET · Ratings
Analysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)
TipRanksMar 12 06:30 ET · Ratings
Corbus Pharmaceuticals | 10-K: FY2024 Annual Report
SECMar 11 17:24 ET · Announcements
Corbus Pharmaceuticals Price Target Cut to $53.00/Share From $70.00 by Jefferies
Dow JonesMar 11 15:23 ET · Ratings
Corbus Pharmaceuticals Is Maintained at Buy by Jefferies
Dow JonesMar 11 15:23 ET · Ratings

Comments

Teddy123

Feb 14 20:36

Medical Research analysis

$Corbus Pharmaceuticals (CRBP.US)$
The Phase 1 clinical trial results for CRB-701 represent a significant advancement in the antibody-drug conjugate (ADC) space, particularly in addressing the historical challenges of ADC toxicity profiles. The observed 4% combined rate of peripheral neuropathy across both Western and Chinese studies is notably lower than existing ADC treatments, where rates can exceed 30-50% with current standard-of-care options.
The drug's differentiat...

Teddy123

Feb 14 20:35

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

$Corbus Pharmaceuticals (CRBP.US)$
Breakthrough Cancer Drug CRB-701 Delivers Powerful Results in Phase 1 Trial: Multiple Tumor Types Respond

Teddy123

Feb 11 20:44

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

$Corbus Pharmaceuticals (CRBP.US)$
Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets